CN112237627A - 用于免疫治疗的二氧化硅纳米球 - Google Patents

用于免疫治疗的二氧化硅纳米球 Download PDF

Info

Publication number
CN112237627A
CN112237627A CN202010693282.3A CN202010693282A CN112237627A CN 112237627 A CN112237627 A CN 112237627A CN 202010693282 A CN202010693282 A CN 202010693282A CN 112237627 A CN112237627 A CN 112237627A
Authority
CN
China
Prior art keywords
hsn
silica
antigen
tumor
neoantigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010693282.3A
Other languages
English (en)
Chinese (zh)
Inventor
牟中原
吴政勋
吴思翰
陈奕平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naili Shengyi Co ltd
Original Assignee
Naili Shengyi Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naili Shengyi Co ltd filed Critical Naili Shengyi Co ltd
Publication of CN112237627A publication Critical patent/CN112237627A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0001—Archaeal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202010693282.3A 2019-07-18 2020-07-17 用于免疫治疗的二氧化硅纳米球 Pending CN112237627A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875842P 2019-07-18 2019-07-18
US62/875,842 2019-07-18

Publications (1)

Publication Number Publication Date
CN112237627A true CN112237627A (zh) 2021-01-19

Family

ID=71670078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010693282.3A Pending CN112237627A (zh) 2019-07-18 2020-07-17 用于免疫治疗的二氧化硅纳米球

Country Status (6)

Country Link
US (1) US12274755B2 (https=)
EP (1) EP3766515A1 (https=)
JP (1) JP2021042193A (https=)
CN (1) CN112237627A (https=)
CA (1) CA3087227A1 (https=)
TW (1) TWI829949B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116999581A (zh) * 2023-08-08 2023-11-07 中南大学湘雅医院 一种靶向治疗乳腺癌的核素纳米药物及其制备方法与应用
CN120590491A (zh) * 2025-05-28 2025-09-05 中科中山药物创新研究院 基于二氧化硅载体的hiv病毒mper多肽纳米疫苗及其制备方法与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114377120B (zh) * 2022-01-10 2023-09-22 大连理工大学 一种以病毒样颗粒为模板的二氧化硅疫苗递送系统的构建及其应用
CN114601817B (zh) * 2022-02-11 2023-01-10 国家纳米科学中心 一种可降解中空有机硅纳米粒子及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229576A1 (en) * 2007-08-14 2011-09-22 The Regents Of The University Of California Hollow silica nanospheres and methods of making same
CN107753464A (zh) * 2016-08-19 2018-03-06 牟中原 囊封有生物活性成分的空心二氧化硅纳米粒子、其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160038608A1 (en) * 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same
JP6868862B2 (ja) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229576A1 (en) * 2007-08-14 2011-09-22 The Regents Of The University Of California Hollow silica nanospheres and methods of making same
CN107753464A (zh) * 2016-08-19 2018-03-06 牟中原 囊封有生物活性成分的空心二氧化硅纳米粒子、其制备方法和应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVID WIBOWO ET AL.: ""Emulsion-templated silica nanocapsules formed using bio-inspired silicification"", 《CHEM. COMMUN.》, vol. 50, 31 December 2014 (2014-12-31), pages 11325 - 11328 *
MARTIN MALMSTEN ET AL.: ""Inorganic nanomaterials as delivery systems for proteins, peptides, DNA, and siRNA"", 《CURRENT OPINION IN COLLOID & INTERFACE SCIENCE》, vol. 18, 21 June 2013 (2013-06-21), pages 468 - 480, XP055343127, DOI: 10.1016/j.cocis.2013.06.002 *
MAXENCE O. DELLACHERIE ET AL.: ""Covalent Conjugation of Peptide Antigen to Mesoporous Silica Rods to Enhance Cellular Responses"", 《BIOCONJUGATE CHEM.》, vol. 29, 10 January 2018 (2018-01-10), pages 733 - 741 *
XIUPENG WANG ET AL.: ""Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres"", 《ANGEW. CHEM.》, vol. 128, 31 December 2016 (2016-12-31), pages 1931 - 1935, XP071370067, DOI: 10.1002/ange.201506179 *
宋文宣等: "《实用心血管病药物治疗学》", vol. 1, 31 August 2001, 人民卫生出版社, pages: 763 - 768 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116999581A (zh) * 2023-08-08 2023-11-07 中南大学湘雅医院 一种靶向治疗乳腺癌的核素纳米药物及其制备方法与应用
CN120590491A (zh) * 2025-05-28 2025-09-05 中科中山药物创新研究院 基于二氧化硅载体的hiv病毒mper多肽纳米疫苗及其制备方法与应用

Also Published As

Publication number Publication date
US20210015943A1 (en) 2021-01-21
CA3087227A1 (en) 2021-01-18
JP2021042193A (ja) 2021-03-18
TW202116292A (zh) 2021-05-01
TWI829949B (zh) 2024-01-21
US12274755B2 (en) 2025-04-15
EP3766515A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
CN112237627A (zh) 用于免疫治疗的二氧化硅纳米球
Li et al. A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
EP0465081B1 (en) Viral decoy vaccine
Cruz et al. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells
Jiang et al. Turning the old adjuvant from gel to nanoparticles to amplify CD8+ T cell responses
US5334394A (en) Human immunodeficiency virus decoy
Cruz et al. Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro
US5462751A (en) Biological and pharmaceutical agents having a nanomeric biodegradable core
Chen et al. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine
EA023397B1 (ru) Комбинированные вакцины с синтетическими наноносителями
Li et al. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
US20080038281A1 (en) Model membrane systems
CN105792843B (zh) 佐剂组合物及包含其的疫苗组合物、以及它们的制造方法
Hu et al. The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine
Cui et al. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor
JP2018115145A (ja) 生物活性成分を内包した中空シリカナノ粒子、調製プロセス、および、その応用
Zhang et al. A dendrimer peptide (KK2DP7) delivery system with dual functions of lymph node targeting and immune adjuvants as a general strategy for cancer immunotherapy
TW201317001A (zh) 粒狀疫苗調配物
Geary et al. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems
US9394369B2 (en) Luminescent porous silicon nanoparticles for targeted delivery and immunization
JP2023529066A (ja) アジュバント／抗原の担体系としてのナノ粒子
Anderluzzi et al. Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses
CA2441809A1 (en) Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
Latif et al. The effect of surface-coupled antigen of liposomes in immunopotentiation
Zhang et al. Polymer–Protein Nanovaccine Synthesized via Reactive Self‐Assembly with Potential Application in Cancer Immunotherapy: Physicochemical and Biological Characterization In Vitro and In Vivo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210119